Research and Markets: Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential

Research and Markets ( http://www.researchandmarkets.com/research/6459a9/big_pharmas_key_l) has announced the addition of the "Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential" report to their offering.

Big Pharma's Key Lifecycle Management Strategies: Maximizing the Market Potential

Big Pharma's Key Lifecycle Management Strategies: Maximizing the Market Potential. It provides key data, information and analysis on the main lifecycle management strategies being implemented by pharmaceutical companies. The report provides information on the lifestyle management strategies (LCM) market, the reasons why companies implement LCM strategies and the challenges faced by them. This report provides comprehensive analysis of five key LCM strategies (new indications, formulation variants, extended/controlled released versions, Rx-to-OTC switches and store brand generics) using case studies. The report also provides the sales growth patterns of the key drugs for which LCM activities are being carried out. It also reviews the factors determining the success and failure of the strategies providing an understanding of how to ensure success for LCM.

It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

Increasing Cost Pressures Will Drive the Growth in LCM Activities

Increasing cost pressures have forced pharmaceutical companies to look for other sources of revenue besides the development of new drugs. The cost of developing a new drug has increased over the years from $54m in 1976 to $280m in 1991 to $1.5 billion in 2004 and is expected to grow further in future. Several blockbuster products such as Lipitor, Plavix, Nexium, Seroquel XR and many others, worth $127 billion currently, are set to expire by 2014. The increasing competition from generics will also continue to erode the revenues of prescription drugs. These factors are expected to drive the pharmaceutical companies to maximize their revenues by minimizing costs. Better management of the lifecycle of the existing brands is a more cost-effective way for pharmaceutical companies to increase revenues than investing money in developing new brands.

Indication Expansion is the Most Popular Form of Lifecycle Management Activity in the Pharmaceutical Industry

This study of the pipelines of 20 major pharmaceutical companies has revealed that indication expansion remains the most popular LCM strategy for their products. Other alternatives include combination therapies, new formulations, dosage variants and extended release formulations. Rx-to-OTC switch also remains one of the popular methods used to manage the lifecycle of drugs whose patents have expired. However, indication expansion activities account for more than 80% of the LCM pipelines for the companies analyzed in this report.

Distribution of LCM Pipeline of 20 Major Pharma Companies by the LCM Strategy Implemented, 2010

The popularity of indication expansion as an LCM strategy is due to its potential to expand the patent pool and extend the drugs market exclusivity. With every expansion providing access to a new patient pool, a company's revenue stream is boosted considerably by this activity. There is at least one project devoted to expanding the indications for almost every drug in the LCM pipeline.

Key Topics Covered:

1 TOC
2 Introduction
3 Lifecycle Management The Next Big Thing for the Pharmaceutical Industry
4 Reasons to Implement Lifecycle Management Increasing Financial Pressures
5 Process of Implementation of Lifecycle Management Strategies Correct Selection and Efficient Execution is the Key
6 The Pharmaceutical Pipeline and LCM Today Cancer and CNS on the Top
7 Ensuring Success of Lifecycle Management Overcoming Challenges
8 Future Outlook LCM to Drive the Profitability and Success Tomorrow
9 Appendix
List of tables
List of figures